This study aimed to compare the anti-proliferative efficacy of lapatinib, neratinib, and tucatinib in a large cancer cell line panel and to identify possible biomarkers of response or resistance to each of these HER2-targeting inhibitors. This evidence concerns the gene ERBB2 and cancer.